AC
SAGE

Athanor Capital’s Sage Therapeutics SAGE Stock Holding History

Athanor Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,974
Closed -$297K – 716
2021
Q1 		$297K Sell
3,974
-808
-17% -$66.2K 0.01% 597
2020
Q4 		$414K Buy
+4,782
New +$352K 0.01% 510
2019
Q3 		– Sell
-1,100
Closed -$201K – 225
2019
Q2 		$201K Buy
+1,100
New +$188K 0.03% 130

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Athanor Capital's SAGE Position: Q2 2021 in Review

Athanor Capital sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 3,974 shares — an estimated $297K sold.

Athanor Capital first reported a position in SAGE in Q2 2019 and held it in 3 quarters. The position peaked at $414K in Q4 2020. 256 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

  • Athanor Capital reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 3,974 Sage Therapeutics shares in Q2 2021, an estimated $297K.
  • Athanor Capital first reported a position in Sage Therapeutics in Q2 2019 and held it in 3 quarters.
  • Athanor Capital's Sage Therapeutics position peaked at $414K in Q4 2020.
  • 256 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.